Literature DB >> 26702627

Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase.

Dennis Tappe1,2, José Vicente Pérez-Girón3, Lorenzo Zammarchi4, Jürgen Rissland5, Davis F Ferreira6, Thomas Jaenisch7, Sergio Gómez-Medina3, Stephan Günther8,9, Alessandro Bartoloni4, César Muñoz-Fontela8,9,3, Jonas Schmidt-Chanasit8,9.   

Abstract

Zika virus is an emerging mosquito-borne flavivirus currently causing large epidemics in the Pacific Ocean region and Brazil. Clinically, Zika fever resembles dengue fever, but is less severe. Whereas the clinical syndrome and laboratory diagnostic procedures have been described, little attention was paid to the immunology of the disease and its possible use for clinical follow-up of patients. Here, we investigate the role of cytokines in the pathogenesis of Zika fever in travelers returning from Asia, the Pacific, and Brazil. Polyfunctional T cell activation (Th1, Th2, Th9, and Th17 response) was seen during the acute phase characterized by respective cytokine level increases, followed by a decrease in the reconvalescent phase.

Entities:  

Keywords:  Arbovirus; Cytokine; Flavivirus; Outbreak; Zika fever; Zika virus

Mesh:

Substances:

Year:  2015        PMID: 26702627      PMCID: PMC4867002          DOI: 10.1007/s00430-015-0445-7

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


Introduction

Zika virus (ZIKV), a mosquito-borne flavivirus, has lately come to international attention owing to outbreaks on Yap Island, Federated States of Micronesia, in 2007 [1] and in French Polynesia beginning in 2013 [2], and a current epidemic after its recent introduction to Brazil [3]. Both epidemics have been attributed to the Asian genotype of ZIKV [2, 3], likely introduced by viremic travelers. The virus is maintained in a natural cycle involving non-human primates and various Aedes mosquito species [4]. ZIKV causes a self-limiting, dengue fever (DF)-like disease with an incubation time of up to 10 days. Signs and symptoms consist of rather low-grade fever, myalgia and a maculopapular rash, accompanied by arthralgia and headache, and less often edema, sore throat, and vomiting [1-4]. In contrast to DF, acute Zika fever (ZF) is less severe; headache and malaise are less intense and haemorrhagic and shock complications have not been reported. Conjunctivitis is often present, whereas arthralgia is less pronounced [1]. However, unusual rates of Guillain Barré syndrome (GBS) were reported in French Polynesia due to ZIKV infection [5]. Laboratory changes include transient leukopenia and in some cases thrombocytopenia. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations may or may not be elevated [6]. Travel-associated infections from both endemic ([6, 7] as examples) and epidemic areas [8, 9] have been documented in non-endemic countries, including the recent report of a patient seen in Italy who became infected in Salvador de Bahia state, Brazil, in the current evolving outbreak. Whereas the clinical syndrome and laboratory diagnostic procedures, including generic and real-time reverse transcription polymerase chain reactions (RT-PCRs) as well as specific non-commercial serology tests and cross-reactions have been described, little attention was paid to the immunology of the disease and its putative use for clinical follow-up of patients. Here, we analyzed serum cytokine levels of travel-associated infections and demonstrate cytokine concentration changes in acute and recovery (reconvalescent) sera. These changes suggested that strong and multifunctional T cell responses are required for recovery from ZIKV infection.

Patients and methods

Sera from six patients (three males, three females) aged 31–62 years (median 41 years) were used for this study. Patients had acquired ZIKV infection in Southeast Asia, Polynesia, or Brazil. Blood was drawn from infected patients at different times after disease onset (4–62 days). Sera were classified as either acute (taken ≤10 days after symptom onset) or recovery (taken >10 days after disease onset). ZIKV infection was diagnosed serologically, and in one case also molecularly by RT-PCR [8]; see Table 1 for details. From all sera, individual multiplex cytokine serum analyses (Bio-Rad Laboratories, Munich, Germany) were performed and 20 sera from healthy blood donors were run in parallel. Written informed consent was obtained from each patient.
Table 1

Characteristics of patients infected with Zika virus included in the study

Patient numberAgeSexSerum taken after disease onset (days)Travel historyReference
153Male31ThailandTappe et al. [6]
233Female35 and 62TahitiZammarchi et al. [8]
331Male33TahitiZammarchi et al. [8]
445Female5 and 10MalaysiaTappe et al. [7]
562Male4 and 26BrazilZammarchi et al. [9]
637Female5BrazilUnpublished
Characteristics of patients infected with Zika virus included in the study

Results

In the acute phase of ZF, significant concentration elevations were found for interleukin (IL)-1b, IL-2, IL-4, IL-6, IL-9, IL-10, IL-13, IL-17, as well as for interferon-γ-induced protein 10 (IP-10), regulated on activation, normal T cell expressed and secreted (RANTES), macrophage inflammatory protein 1 alpha (MIP-1a) and vascular endothelial growth factor (VEGF), when compared to normal controls. In the recovery phase, significant increases were demonstrated in the levels of IL-1b, IL-6, IL-8, IL-10, IL-13, as well as of IP-10, RANTES, MIP-1a, MIP-1b, and VEGF, fibroblast growth factor (FGF), granulocyte-macrophage colony stimulating factor (GM-CSF), in comparison with healthy controls. Interferon-γ (IFN-γ) levels showed an increasing trend in the acute and recovery phase (non-significant), whereas tumor necrosis factor-α (TNF-α) concentrations only showed a median increase during the acute phase (also non-significant). Many of the cytokines and factors that were elevated in the acute phase showed a tendency to return to normal levels in the later recovery phase (Figs. 1, 2).
Fig. 1

Changes in cytokine levels in the acute and recovery phase of Zika fever. With the exception of IL-8, significant elevations of the serum interleukin concentrations are evident in the early, acute phase of Zika fever. In the recovery phase, IL-1b, IL-8, and IL-10 levels were higher than in the acute phase, whereas levels of the other depicted cytokines were declining. Box-and-whisker plots showing median, upper and lower quartile, minimum, and maximum values. *P < 0.05, **P < 0.01, ***P < 0.001, versus healthy controls (Kruskal–Wallis test)

Fig. 2

Changes in cytokine and growth factor levels in the acute and recovery phase of Zika fever. RANTES, MIP-1a, and VEGF levels were higher in the acute than in the recovery phase, whereas IP-10, MIP-1b, and GM-CSF reached higher concentrations in the recovery phase than during acute infection. IFN-γ levels showed a non-significant, however, increasing trend over the course of infection, whereas TNF-α concentrations only displayed a non-significant median increase in the acute phase. Box-and-whisker plots showing median, upper and lower quartile, minimum, and maximum values. *P < 0.05, **P < 0.01, ***P < 0.001, versus healthy controls (Kruskal–Wallis test)

Changes in cytokine levels in the acute and recovery phase of Zika fever. With the exception of IL-8, significant elevations of the serum interleukin concentrations are evident in the early, acute phase of Zika fever. In the recovery phase, IL-1b, IL-8, and IL-10 levels were higher than in the acute phase, whereas levels of the other depicted cytokines were declining. Box-and-whisker plots showing median, upper and lower quartile, minimum, and maximum values. *P < 0.05, **P < 0.01, ***P < 0.001, versus healthy controls (Kruskal–Wallis test) Changes in cytokine and growth factor levels in the acute and recovery phase of Zika fever. RANTES, MIP-1a, and VEGF levels were higher in the acute than in the recovery phase, whereas IP-10, MIP-1b, and GM-CSF reached higher concentrations in the recovery phase than during acute infection. IFN-γ levels showed a non-significant, however, increasing trend over the course of infection, whereas TNF-α concentrations only displayed a non-significant median increase in the acute phase. Box-and-whisker plots showing median, upper and lower quartile, minimum, and maximum values. *P < 0.05, **P < 0.01, ***P < 0.001, versus healthy controls (Kruskal–Wallis test) No significant changes, neither in the acute nor in the recovery phase, could be observed for IL-1ra, IL-5, IL-7, IL-12, monocyte chemotactic protein 1 (MCP-1), eotaxin, and platelet-derived growth factor-bb (PDGF-bb; data not shown). There were no significant changes between any of the cytokine levels measured in the acute versus the recovery phase.

Discussion

In contrast to the clinically similar DF, acute ZIKV infections are less severe and secondary infections are not described owing to the fact that only one serotype of ZIKV exists. After an acute ZIKV infection immunity to re-infection is established for an unknown time span, based on epidemiological evidence from past outbreaks [1, 2]. In the patients studied here, elevation of chemokines was more pronounced than elevation of cytokines. In the recovery phase, cytokine levels generally decreased. A polyfunctional immune activation was seen during the acute phase of ZF, as reflected by elevated cytokine profiles associated with Th1 (IL-2, and non-significantly IFN-γ), Th2 (IL-4, IL-13), Th17 (IL-17), and also Th9 (IL-9) responses. Data on IL-9 functions during human viral infection is scarce, but studies have shown an association of elevated IL-9 levels and severe acute respiratory syncytial virus infections [10] and non-response to treatment of chronic hepatitis C [11], suggesting a modulator role of antiviral immunity. In our study, IL-2, IFN-γ and TNF-α levels were surprisingly lower than expected, contrasting with findings in other arboviral infections [12, 13]. Of note, in our study RANTES is already increased in the acute phase, whereas IP-10 is particularly elevated in the recovery phase. Effective T cell recruitment to infection sites and formation of effector T cells was suggested by both increased RANTES and IP-10 concentrations [14, 15]. Since CCR5 and CxCR3 are chemokine ligands receptors for RANTES and IP-10, respectively, immunophenotyping of peripheral blood T cells of ZIKV-infected patients as well as functional T cell assays should help to further explore the role of RANTES and IP-10 during ZF. Similar to descriptions of patients infected with dengue virus (DENV) [16], a related flavivirus, sera of patients with ZF analyzed in our study also showed increased IL-4, IL-6, IL-8, IL-10, and IP-10 levels. IL-10 levels were also highest in the later (recovery) phase of ZIKV infection, as seen in DF [14]. In contrast to DF, however, concentrations of IL-1ß, IL-2, MCP-1, and VEGF were not decreased in ZF patients. In DF, elevated IL-8 and IL-10 levels were shown to be associated with severe infection [14], a clinical state which has so far not been seen in ZF. No “cytokine storm effects”, as known from DENV infections [17] were demonstrated in the ZF patients in our study. Of note, significantly increased IFN-γ and TNF-α levels were absent in ZF in contrast to DF, pointing toward a Th2 bias in ZIKV infections. In DENV infections, thrombocytopenia correlated strongly with RANTES and VEGF levels [16]. Both RANTES, a chemokine stored in a-granules of platelets, secreted upon platelet activation, and VEGF, a growth factor released by platelets, would be expected to decrease upon thrombocytopenia. In contrast, severe thrombocytopenia is rarely observed in ZF patients and RANTES and VEGF did not show decreased levels when compared with the control group. It remains to be elucidated whether ZIKV-induced GBS [5] might be associated with different cytokine responses than changes in non-GBS ZIKV-infected patients. Due to the small number of ZF patients examined, this study and the strength of the observations are limited. We have analyzed cytokine levels over time in returning travelers to Europe, and it is unknown whether different human ethnic groups might show different cytokine responses as described for DF [18]. Recent ZF epidemics were only caused by the Asian genotype of ZIKV, which is the same genotype also seen in travel-related infections from outbreak areas. Thus, the cytokine data presented here are linked to an infection with the Asian genotype. As a restriction of the study, functional T cell tests (i.e., stimulation with ZIKV antigen followed by intracellular cytokine staining) have not been performed. Future studies will address lymphocyte and cytokine responses in more detail, allowing proper conclusions of Th1- and Th2-biased cell responses. Despite showing rather preliminary data, to our knowledge, this is the first study investigating immune parameters in acute ZF.
  18 in total

Review 1.  Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS).

Authors:  Tikki Pang; Mary Jane Cardosa; Maria G Guzman
Journal:  Immunol Cell Biol       Date:  2006-11-28       Impact factor: 5.126

Review 2.  Dengue pathogenesis: a disease driven by the host response.

Authors:  Byron E E Martina
Journal:  Sci Prog       Date:  2014       Impact factor: 2.774

3.  Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications.

Authors:  Lorenzo Zammarchi; Giulia Stella; Antonia Mantella; Dario Bartolozzi; Dennis Tappe; Stephan Günther; Lisa Oestereich; Daniel Cadar; César Muñoz-Fontela; Alessandro Bartoloni; Jonas Schmidt-Chanasit
Journal:  J Clin Virol       Date:  2014-12-12       Impact factor: 3.168

4.  Serum levels of cytokines in two ethnic groups with dengue virus infection.

Authors:  Berta N Restrepo; Ruth E Ramirez; Margarita Arboleda; Gonzalo Alvarez; Marta Ospina; Francisco J Diaz
Journal:  Am J Trop Med Hyg       Date:  2008-11       Impact factor: 2.345

5.  Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013.

Authors:  E Oehler; L Watrin; P Larre; I Leparc-Goffart; S Lastere; F Valour; L Baudouin; Hp Mallet; D Musso; F Ghawche
Journal:  Euro Surveill       Date:  2014-03-06

Review 6.  Dengue virus infection: current concepts in immune mechanisms and lessons from murine models.

Authors:  Rodrigo Guabiraba; Bernhard Ryffel
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

7.  Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue fever.

Authors:  Luzia Maria de-Oliveira-Pinto; Cíntia Ferreira Marinho; Tiago Fajardo Povoa; Elzinandes Leal de Azeredo; Luiza Assed de Souza; Luiza Damian Ribeiro Barbosa; Ana Rita C Motta-Castro; Ada M B Alves; Carlos André Lins Ávila; Luiz José de Souza; Rivaldo Venâncio da Cunha; Paulo Vieira Damasco; Marciano Viana Paes; Claire Fernandes Kubelka
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

8.  First report of autochthonous transmission of Zika virus in Brazil.

Authors:  Camila Zanluca; Vanessa Campos Andrade de Melo; Ana Luiza Pamplona Mosimann; Glauco Igor Viana Dos Santos; Claudia Nunes Duarte Dos Santos; Kleber Luz
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-06-09       Impact factor: 2.743

9.  Zika virus, French polynesia, South pacific, 2013.

Authors:  Van-Mai Cao-Lormeau; Claudine Roche; Anita Teissier; Emilie Robin; Anne-Laure Berry; Henri-Pierre Mallet; Amadou Alpha Sall; Didier Musso
Journal:  Emerg Infect Dis       Date:  2014-06       Impact factor: 6.883

10.  Cytokine expression profile of dengue patients at different phases of illness.

Authors:  Anusyah Rathakrishnan; Seok Mui Wang; Yongli Hu; Asif M Khan; Sasheela Ponnampalavanar; Lucy Chai See Lum; Rishya Manikam; Shamala Devi Sekaran
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more
  76 in total

Review 1.  Evaluation of Possible Consequences of Zika Virus Infection in the Developing Nervous System.

Authors:  Lais Takata Walter; Guilherme Shigueto Vilar Higa; Juliane Midori Ikebara; Danila Vedovello; Felipe Scassi Salvador; Silvia Honda Takada; Erika Reime Kinjo; Benjamin J Whalley; Márcia Aparecida Sperança; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2017-02-11       Impact factor: 5.590

2.  IL-1 receptor antagonist therapy mitigates placental dysfunction and perinatal injury following Zika virus infection.

Authors:  Jun Lei; Meghan S Vermillion; Bei Jia; Han Xie; Li Xie; Michael W McLane; Jeanne S Sheffield; Andrew Pekosz; Amanda Brown; Sabra L Klein; Irina Burd
Journal:  JCI Insight       Date:  2019-02-28

Review 3.  Host-Virus Interaction of ZIKA Virus in Modulating Disease Pathogenesis.

Authors:  Nanda Kishore Routhu; Siddappa N Byrareddy
Journal:  J Neuroimmune Pharmacol       Date:  2017-03-27       Impact factor: 4.147

4.  Specific Biomarkers Associated With Neurological Complications and Congenital Central Nervous System Abnormalities From Zika Virus-Infected Patients in Brazil.

Authors:  Yiu-Wing Kam; Juliana Almeida Leite; Fok-Moon Lum; Jeslin J L Tan; Bernett Lee; Carla C Judice; Daniel Augusto de Toledo Teixeira; Robert Andreata-Santos; Marco A Vinolo; Rodrigo Angerami; Mariangela Ribeiro Resende; Andre Ricardo Ribas Freitas; Eliana Amaral; Renato Passini Junior; Maria Laura Costa; José Paulo Guida; Clarice Weis Arns; Luis Carlos S Ferreira; Laurent Rénia; Jose Luiz Proença-Modena; Lisa F P Ng; Fabio T M Costa
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

Review 5.  Zika Virus Infection: Current Concerns and Perspectives.

Authors:  Mari Kannan Maharajan; Aruna Ranjan; Jian Feng Chu; Wei Lim Foo; Zhi Xin Chai; Eileen YinYien Lau; Heuy Mien Ye; Xi Jin Theam; Yen Ling Lok
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

6.  Newborns With Zika Virus-Associated Microcephaly Exhibit Marked Systemic Inflammatory Imbalance.

Authors:  Caian L Vinhaes; María B Arriaga; Breno L de Almeida; João V Oliveira; Cleiton S Santos; Juan I Calcagno; Tereza X Carvalho; Marta Giovanetti; Luiz Carlos J Alcantara; Isadora C de Siqueira; Bruno B Andrade
Journal:  J Infect Dis       Date:  2020-07-23       Impact factor: 5.226

7.  Translational Model of Zika Virus Disease in Baboons.

Authors:  Sunam Gurung; Alisha N Preno; Jamie P Dubaut; Hugh Nadeau; Kimberly Hyatt; Nicole Reuter; Bharti Nehete; Roman F Wolf; Pramod Nehete; Dirk P Dittmer; Dean A Myers; James F Papin
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

8.  Modeling neuro-immune interactions during Zika virus infection.

Authors:  Pinar Mesci; Angela Macia; Christopher N LaRock; Leon Tejwani; Isabella R Fernandes; Nicole A Suarez; Paolo M de A Zanotto; Patricia C B Beltrão-Braga; Victor Nizet; Alysson R Muotri
Journal:  Hum Mol Genet       Date:  2018-01-01       Impact factor: 6.150

Review 9.  Taking the defensive: Immune control of Zika virus infection.

Authors:  James R Bowen; Matthew G Zimmerman; Mehul S Suthar
Journal:  Virus Res       Date:  2017-09-01       Impact factor: 3.303

Review 10.  Zika Virus as an Emerging Global Pathogen: Neurological Complications of Zika Virus.

Authors:  J David Beckham; Daniel M Pastula; Aaron Massey; Kenneth L Tyler
Journal:  JAMA Neurol       Date:  2016-07-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.